APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ondansetron Oral Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Ondansetron Oral Drugs Industry Research Report 2026

27 December 2025134 pages

Choose your research edition.

Industry ResearchOndansetron Oral Drugs Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Ondansetron Oral Drugs Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Ondansetron Oral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ondansetron Oral Drugs Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Ondansetron Oral Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Ondansetron Oral Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Ondansetron Oral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Ondansetron Oral Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Ondansetron Oral Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Ondansetron Oral Drugs include GSK, SJZ No.4 Pharmaceutical, Shanghai Pharmaceuticals, Qilu Pharmaceutical, Ningbo Tianheng Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Sinopharm, PKU Healthcare and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Ondansetron Oral Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Ondansetron Oral Drugs Market by Company

GSK

SJZ No.4 Pharmaceutical

Shanghai Pharmaceuticals

Qilu Pharmaceutical

Ningbo Tianheng Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Sinopharm

PKU Healthcare

Teva

Takeda

Novartis

Mylan

Morningside Pharmaceuticals

Henry Schein

Aurobindo Pharma

Aden Healthcare

Ondansetron Oral Drugs Segment by Type

Capsules

Oral Solution

Oral Soluble Pellicles

Tablets

Other

Ondansetron Oral Drugs Segment by Application

Hospital and Clinic

Pharmacy

Other

Ondansetron Oral Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ondansetron Oral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ondansetron Oral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ondansetron Oral Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Ondansetron Oral Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Ondansetron Oral Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Ondansetron Oral Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Ondansetron Oral Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Ondansetron Oral Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Ondansetron Oral Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Ondansetron Oral Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Ondansetron Oral Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Ondansetron Oral Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Ondansetron Oral Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Ondansetron Oral Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Ondansetron Oral Drugs, Product Type & Application Table 14. Global Ondansetron Oral Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Ondansetron Oral Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. GSK Company Information Table 19. GSK Business Overview Table 20. GSK Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. GSK Ondansetron Oral Drugs Product Portfolio Table 22. GSK Recent Developments Table 23. SJZ No.4 Pharmaceutical Company Information Table 24. SJZ No.4 Pharmaceutical Business Overview Table 25. SJZ No.4 Pharmaceutical Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. SJZ No.4 Pharmaceutical Ondansetron Oral Drugs Product Portfolio Table 27. SJZ No.4 Pharmaceutical Recent Developments Table 28. Shanghai Pharmaceuticals Company Information Table 29. Shanghai Pharmaceuticals Business Overview Table 30. Shanghai Pharmaceuticals Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Shanghai Pharmaceuticals Ondansetron Oral Drugs Product Portfolio Table 32. Shanghai Pharmaceuticals Recent Developments Table 33. Qilu Pharmaceutical Company Information Table 34. Qilu Pharmaceutical Business Overview Table 35. Qilu Pharmaceutical Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Qilu Pharmaceutical Ondansetron Oral Drugs Product Portfolio Table 37. Qilu Pharmaceutical Recent Developments Table 38. Ningbo Tianheng Pharmaceutical Company Information Table 39. Ningbo Tianheng Pharmaceutical Business Overview Table 40. Ningbo Tianheng Pharmaceutical Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Ningbo Tianheng Pharmaceutical Ondansetron Oral Drugs Product Portfolio Table 42. Ningbo Tianheng Pharmaceutical Recent Developments Table 43. Jiangsu Hengrui Pharmaceuticals Company Information Table 44. Jiangsu Hengrui Pharmaceuticals Business Overview Table 45. Jiangsu Hengrui Pharmaceuticals Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Jiangsu Hengrui Pharmaceuticals Ondansetron Oral Drugs Product Portfolio Table 47. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 48. Sinopharm Company Information Table 49. Sinopharm Business Overview Table 50. Sinopharm Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sinopharm Ondansetron Oral Drugs Product Portfolio Table 52. Sinopharm Recent Developments Table 53. PKU Healthcare Company Information Table 54. PKU Healthcare Business Overview Table 55. PKU Healthcare Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. PKU Healthcare Ondansetron Oral Drugs Product Portfolio Table 57. PKU Healthcare Recent Developments Table 58. Teva Company Information Table 59. Teva Business Overview Table 60. Teva Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Teva Ondansetron Oral Drugs Product Portfolio Table 62. Teva Recent Developments Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Takeda Ondansetron Oral Drugs Product Portfolio Table 67. Takeda Recent Developments Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novartis Ondansetron Oral Drugs Product Portfolio Table 72. Novartis Recent Developments Table 73. Mylan Company Information Table 74. Mylan Business Overview Table 75. Mylan Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Mylan Ondansetron Oral Drugs Product Portfolio Table 77. Mylan Recent Developments Table 78. Morningside Pharmaceuticals Company Information Table 79. Morningside Pharmaceuticals Business Overview Table 80. Morningside Pharmaceuticals Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Morningside Pharmaceuticals Ondansetron Oral Drugs Product Portfolio Table 82. Morningside Pharmaceuticals Recent Developments Table 83. Henry Schein Company Information Table 84. Henry Schein Business Overview Table 85. Henry Schein Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Henry Schein Ondansetron Oral Drugs Product Portfolio Table 87. Henry Schein Recent Developments Table 88. Aurobindo Pharma Company Information Table 89. Aurobindo Pharma Business Overview Table 90. Aurobindo Pharma Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Aurobindo Pharma Ondansetron Oral Drugs Product Portfolio Table 92. Aurobindo Pharma Recent Developments Table 93. Aden Healthcare Company Information Table 94. Aden Healthcare Business Overview Table 95. Aden Healthcare Ondansetron Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Aden Healthcare Ondansetron Oral Drugs Product Portfolio Table 97. Aden Healthcare Recent Developments Table 98. Global Ondansetron Oral Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Ondansetron Oral Drugs Sales by Region (2021-2026) & (K Units) Table 100. Global Ondansetron Oral Drugs Sales Market Share by Region (2021-2026) Table 101. Global Ondansetron Oral Drugs Sales by Region (2027-2032) & (K Units) Table 102. Global Ondansetron Oral Drugs Sales Market Share by Region (2027-2032) Table 103. Global Ondansetron Oral Drugs Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Ondansetron Oral Drugs Revenue Market Share by Region (2021-2026) Table 105. Global Ondansetron Oral Drugs Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Ondansetron Oral Drugs Revenue Market Share by Region (2027-2032) Table 107. North America Ondansetron Oral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Ondansetron Oral Drugs Sales by Country (2021-2026) & (K Units) Table 109. North America Ondansetron Oral Drugs Sales by Country (2027-2032) & (K Units) Table 110. North America Ondansetron Oral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Ondansetron Oral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Ondansetron Oral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Ondansetron Oral Drugs Sales by Country (2021-2026) & (K Units) Table 114. Europe Ondansetron Oral Drugs Sales by Country (2027-2032) & (K Units) Table 115. Europe Ondansetron Oral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Ondansetron Oral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Ondansetron Oral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Ondansetron Oral Drugs Sales by Country (2021-2026) & (K Units) Table 119. Asia Pacific Ondansetron Oral Drugs Sales by Country (2027-2032) & (K Units) Table 120. Asia Pacific Ondansetron Oral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Ondansetron Oral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Ondansetron Oral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Ondansetron Oral Drugs Sales by Country (2021-2026) & (K Units) Table 124. South America Ondansetron Oral Drugs Sales by Country (2027-2032) & (K Units) Table 125. South America Ondansetron Oral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Ondansetron Oral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Ondansetron Oral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Ondansetron Oral Drugs Sales by Country (2021-2026) & (K Units) Table 129. Middle East and Africa Ondansetron Oral Drugs Sales by Country (2027-2032) & (K Units) Table 130. Middle East and Africa Ondansetron Oral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Ondansetron Oral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Ondansetron Oral Drugs Sales by Type (2021-2026) & (K Units) Table 133. Global Ondansetron Oral Drugs Sales by Type (2027-2032) & (K Units) Table 134. Global Ondansetron Oral Drugs Sales Market Share by Type (2021-2026) Table 135. Global Ondansetron Oral Drugs Sales Market Share by Type (2027-2032) Table 136. Global Ondansetron Oral Drugs Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Ondansetron Oral Drugs Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Ondansetron Oral Drugs Revenue Market Share by Type (2021-2026) Table 139. Global Ondansetron Oral Drugs Revenue Market Share by Type (2027-2032) Table 140. Global Ondansetron Oral Drugs Price by Type (2021-2026) & (US$/Unit) Table 141. Global Ondansetron Oral Drugs Price by Type (2027-2032) & (US$/Unit) Table 142. Global Ondansetron Oral Drugs Sales by Application (2021-2026) & (K Units) Table 143. Global Ondansetron Oral Drugs Sales by Application (2027-2032) & (K Units) Table 144. Global Ondansetron Oral Drugs Sales Market Share by Application (2021-2026) Table 145. Global Ondansetron Oral Drugs Sales Market Share by Application (2027-2032) Table 146. Global Ondansetron Oral Drugs Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Ondansetron Oral Drugs Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Ondansetron Oral Drugs Revenue Market Share by Application (2021-2026) Table 149. Global Ondansetron Oral Drugs Revenue Market Share by Application (2027-2032) Table 150. Global Ondansetron Oral Drugs Price by Application (2021-2026) & (US$/Unit) Table 151. Global Ondansetron Oral Drugs Price by Application (2027-2032) & (US$/Unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Ondansetron Oral Drugs Distributors List Table 155. Ondansetron Oral Drugs Customers List Table 156. Ondansetron Oral Drugs Industry Trends Table 157. Ondansetron Oral Drugs Industry Drivers Table 158. Ondansetron Oral Drugs Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Ondansetron Oral Drugs Product Image Figure 5. Global Ondansetron Oral Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Ondansetron Oral Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Ondansetron Oral Drugs Sales (2021-2032) & (K Units) Figure 8. Global Ondansetron Oral Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Capsules Product Image Figure 10. Oral Solution Product Image Figure 11. Oral Soluble Pellicles Product Image Figure 12. Tablets Product Image Figure 13. Other Product Image Figure 14. Hospital and Clinic Product Image Figure 15. Pharmacy Product Image Figure 16. Other Product Image Figure 17. Global Ondansetron Oral Drugs Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Ondansetron Oral Drugs, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Ondansetron Oral Drugs Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Ondansetron Oral Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Ondansetron Oral Drugs Sales by Region in 2025 Figure 23. Global Ondansetron Oral Drugs Revenue by Region in 2025 Figure 24. North America Ondansetron Oral Drugs Market Size by Country in 2025 Figure 25. North America Ondansetron Oral Drugs Sales Market Share by Country (2021-2032) Figure 26. North America Ondansetron Oral Drugs Revenue Market Share by Country (2021-2032) Figure 27. United States Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Ondansetron Oral Drugs Market Size by Country in 2025 Figure 31. Europe Ondansetron Oral Drugs Sales Market Share by Country (2021-2032) Figure 32. Europe Ondansetron Oral Drugs Revenue Market Share by Country (2021-2032) Figure 33. Germany Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Ondansetron Oral Drugs Market Size by Country in 2025 Figure 44. Asia Pacific Ondansetron Oral Drugs Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Ondansetron Oral Drugs Revenue Market Share by Country (2021-2032) Figure 46. China Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Ondansetron Oral Drugs Market Size by Country in 2025 Figure 55. South America Ondansetron Oral Drugs Sales Market Share by Country (2021-2032) Figure 56. South America Ondansetron Oral Drugs Revenue Market Share by Country (2021-2032) Figure 57. Brazil Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Colombia Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Ondansetron Oral Drugs Market Size by Country in 2025 Figure 62. Middle East and Africa Ondansetron Oral Drugs Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Ondansetron Oral Drugs Revenue Market Share by Country (2021-2032) Figure 64. Egypt Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Ondansetron Oral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Ondansetron Oral Drugs Sales Market Share by Type (2021-2032) Figure 70. Global Ondansetron Oral Drugs Revenue Market Share by Type (2021-2032) Figure 71. Global Ondansetron Oral Drugs Price (US$/Unit) by Type (2021-2032) Figure 72. Global Ondansetron Oral Drugs Sales Market Share by Application (2021-2032) Figure 73. Global Ondansetron Oral Drugs Revenue Market Share by Application (2021-2032) Figure 74. Global Ondansetron Oral Drugs Price (US$/Unit) by Application (2021-2032) Figure 75. Ondansetron Oral Drugs Value Chain Figure 76. Ondansetron Oral Drugs Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Ondansetron Oral Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Capsules
  • Oral Solution
  • Oral Soluble Pellicles
  • Tablets
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • GSK
  • SJZ No.4 Pharmaceutical
  • Shanghai Pharmaceuticals
  • Qilu Pharmaceutical
  • Ningbo Tianheng Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Sinopharm
  • PKU Healthcare
  • Teva
  • Takeda
  • Novartis
  • Mylan
  • Morningside Pharmaceuticals
  • Henry Schein
  • Aurobindo Pharma
  • Aden Healthcare

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Ondansetron Oral Drugs Market Size (2021-2032)
  4. 2.2.2 Global Ondansetron Oral Drugs Sales (2021-2032)
  5. 2.2.3 Global Ondansetron Oral Drugs Market Average Price (2021-2032)
  6. 2.3 Ondansetron Oral Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Capsules
  9. 2.3.3 Oral Solution
  10. 2.3.4 Oral Soluble Pellicles
  11. 2.3.5 Tablets
  12. 2.3.6 Other
  13. 2.4 Ondansetron Oral Drugs by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital and Clinic
  16. 2.4.3 Pharmacy
  17. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Ondansetron Oral Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Ondansetron Oral Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Ondansetron Oral Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Ondansetron Oral Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Ondansetron Oral Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Ondansetron Oral Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Ondansetron Oral Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Ondansetron Oral Drugs, Established Date
  9. 3.9 Global Ondansetron Oral Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 GSK
  2. 4.1.1 GSK Company Information
  3. 4.1.2 GSK Business Overview
  4. 4.1.3 GSK Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 GSK Ondansetron Oral Drugs Product Portfolio
  6. 4.1.5 GSK Recent Developments
  7. 4.2 SJZ No.4 Pharmaceutical
  8. 4.2.1 SJZ No.4 Pharmaceutical Company Information
  9. 4.2.2 SJZ No.4 Pharmaceutical Business Overview
  10. 4.2.3 SJZ No.4 Pharmaceutical Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 SJZ No.4 Pharmaceutical Ondansetron Oral Drugs Product Portfolio
  12. 4.2.5 SJZ No.4 Pharmaceutical Recent Developments
  13. 4.3 Shanghai Pharmaceuticals
  14. 4.3.1 Shanghai Pharmaceuticals Company Information
  15. 4.3.2 Shanghai Pharmaceuticals Business Overview
  16. 4.3.3 Shanghai Pharmaceuticals Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Shanghai Pharmaceuticals Ondansetron Oral Drugs Product Portfolio
  18. 4.3.5 Shanghai Pharmaceuticals Recent Developments
  19. 4.4 Qilu Pharmaceutical
  20. 4.4.1 Qilu Pharmaceutical Company Information
  21. 4.4.2 Qilu Pharmaceutical Business Overview
  22. 4.4.3 Qilu Pharmaceutical Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Qilu Pharmaceutical Ondansetron Oral Drugs Product Portfolio
  24. 4.4.5 Qilu Pharmaceutical Recent Developments
  25. 4.5 Ningbo Tianheng Pharmaceutical
  26. 4.5.1 Ningbo Tianheng Pharmaceutical Company Information
  27. 4.5.2 Ningbo Tianheng Pharmaceutical Business Overview
  28. 4.5.3 Ningbo Tianheng Pharmaceutical Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Ningbo Tianheng Pharmaceutical Ondansetron Oral Drugs Product Portfolio
  30. 4.5.5 Ningbo Tianheng Pharmaceutical Recent Developments
  31. 4.6 Jiangsu Hengrui Pharmaceuticals
  32. 4.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
  33. 4.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  34. 4.6.3 Jiangsu Hengrui Pharmaceuticals Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Jiangsu Hengrui Pharmaceuticals Ondansetron Oral Drugs Product Portfolio
  36. 4.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  37. 4.7 Sinopharm
  38. 4.7.1 Sinopharm Company Information
  39. 4.7.2 Sinopharm Business Overview
  40. 4.7.3 Sinopharm Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sinopharm Ondansetron Oral Drugs Product Portfolio
  42. 4.7.5 Sinopharm Recent Developments
  43. 4.8 PKU Healthcare
  44. 4.8.1 PKU Healthcare Company Information
  45. 4.8.2 PKU Healthcare Business Overview
  46. 4.8.3 PKU Healthcare Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 PKU Healthcare Ondansetron Oral Drugs Product Portfolio
  48. 4.8.5 PKU Healthcare Recent Developments
  49. 4.9 Teva
  50. 4.9.1 Teva Company Information
  51. 4.9.2 Teva Business Overview
  52. 4.9.3 Teva Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Teva Ondansetron Oral Drugs Product Portfolio
  54. 4.9.5 Teva Recent Developments
  55. 4.10 Takeda
  56. 4.10.1 Takeda Company Information
  57. 4.10.2 Takeda Business Overview
  58. 4.10.3 Takeda Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Takeda Ondansetron Oral Drugs Product Portfolio
  60. 4.10.5 Takeda Recent Developments
  61. 4.11 Novartis
  62. 4.11.1 Novartis Company Information
  63. 4.11.2 Novartis Business Overview
  64. 4.11.3 Novartis Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Novartis Ondansetron Oral Drugs Product Portfolio
  66. 4.11.5 Novartis Recent Developments
  67. 4.12 Mylan
  68. 4.12.1 Mylan Company Information
  69. 4.12.2 Mylan Business Overview
  70. 4.12.3 Mylan Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Mylan Ondansetron Oral Drugs Product Portfolio
  72. 4.12.5 Mylan Recent Developments
  73. 4.13 Morningside Pharmaceuticals
  74. 4.13.1 Morningside Pharmaceuticals Company Information
  75. 4.13.2 Morningside Pharmaceuticals Business Overview
  76. 4.13.3 Morningside Pharmaceuticals Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Morningside Pharmaceuticals Ondansetron Oral Drugs Product Portfolio
  78. 4.13.5 Morningside Pharmaceuticals Recent Developments
  79. 4.14 Henry Schein
  80. 4.14.1 Henry Schein Company Information
  81. 4.14.2 Henry Schein Business Overview
  82. 4.14.3 Henry Schein Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Henry Schein Ondansetron Oral Drugs Product Portfolio
  84. 4.14.5 Henry Schein Recent Developments
  85. 4.15 Aurobindo Pharma
  86. 4.15.1 Aurobindo Pharma Company Information
  87. 4.15.2 Aurobindo Pharma Business Overview
  88. 4.15.3 Aurobindo Pharma Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Aurobindo Pharma Ondansetron Oral Drugs Product Portfolio
  90. 4.15.5 Aurobindo Pharma Recent Developments
  91. 4.16 Aden Healthcare
  92. 4.16.1 Aden Healthcare Company Information
  93. 4.16.2 Aden Healthcare Business Overview
  94. 4.16.3 Aden Healthcare Ondansetron Oral Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Aden Healthcare Ondansetron Oral Drugs Product Portfolio
  96. 4.16.5 Aden Healthcare Recent Developments
5 Global Ondansetron Oral Drugs Market Scenario by Region
  1. 5.1 Global Ondansetron Oral Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Ondansetron Oral Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Ondansetron Oral Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Ondansetron Oral Drugs Sales by Region: 2027-2032
  5. 5.3 Global Ondansetron Oral Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Ondansetron Oral Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Ondansetron Oral Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Ondansetron Oral Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Ondansetron Oral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Ondansetron Oral Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Ondansetron Oral Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Ondansetron Oral Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Ondansetron Oral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Ondansetron Oral Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Ondansetron Oral Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Ondansetron Oral Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Ondansetron Oral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Ondansetron Oral Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Ondansetron Oral Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Ondansetron Oral Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Ondansetron Oral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Ondansetron Oral Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Ondansetron Oral Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Ondansetron Oral Drugs Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Ondansetron Oral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Ondansetron Oral Drugs Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Ondansetron Oral Drugs Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Ondansetron Oral Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Ondansetron Oral Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Ondansetron Oral Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Ondansetron Oral Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Ondansetron Oral Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Ondansetron Oral Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Ondansetron Oral Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Ondansetron Oral Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Ondansetron Oral Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Ondansetron Oral Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Ondansetron Oral Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Ondansetron Oral Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Ondansetron Oral Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Ondansetron Oral Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Ondansetron Oral Drugs Value Chain Analysis
  2. 8.1.1 Ondansetron Oral Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Ondansetron Oral Drugs Production Mode & Process
  5. 8.2 Ondansetron Oral Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Ondansetron Oral Drugs Distributors
  8. 8.2.3 Ondansetron Oral Drugs Customers
9 Global Ondansetron Oral Drugs Analyzing Market Dynamics
  1. 9.1 Ondansetron Oral Drugs Industry Trends
  2. 9.2 Ondansetron Oral Drugs Industry Drivers
  3. 9.3 Ondansetron Oral Drugs Industry Opportunities and Challenges
  4. 9.4 Ondansetron Oral Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst